Healthcare Industry News: aspirin
News Release - October 26, 2006
Lipicard's Platrol(R) - First Safe, Sustained Release Antiplatelet Drug Developed Through a Novel Platform Technology
HYDERABAD, India--(HSMN NewsFeed)--Platrol® has demonstrated 40% more efficacy and negligible toxicity resulting in higher therapeutic index compared to aspirin, Clopidogrel and other anti-platelet drugs in clinical trials. Surprisingly, its inherent sustained release property makes Platrol® even better as a long-term cardio-protective drug.Pioneering studies by Garret Fitzgerald at the University of Pennsylvania and other scientists in the 80's have shown that a controlled release formulation of aspirin at the correct release rate will result in sustained specific irreversible acetylation of platelets as they pass through the portal circulation. This will enhance action of aspirin in endothelium, but mitigating its anti-aspirin like activity if released into the systemic circulation.
Recent human pharmacokinetic studies have shown that Platrol® behaves like a sustained release formulation. Also, the absence of known active metabolite in the systemic circulation in humans explains both its higher efficacy in portal circulation and lower systemic toxicity.
Platrol®, we believe acts similar to aspirin - decreasing the blood clotting by dual mechanism - by inhibiting the Thromboxane A2 synthesis and through chemical acetylation of the blood platelets.
However, unlike aspirin, Platrol® does not have the acidic group intact. Several GI irritation studies in a sensitive rat model showed Platrol® is devoid of this toxicity, while aspirin caused acute severe hemorrhage and ulcers in the stomach.
As reported earlier, Platrol® is far superior to all other drugs in the research pipeline including the Nitric Oxide (NO) donating derivatives of aspirin. Lipicard's survey also revealed that US cardiologists are ready to prescribe Platrol® as and when it is available due to its higher efficacy and lower toxicity than aspirin.
Lipicard will share the details and profile of other safe drugs developed using a novel platform technology "Athena" soon.
About Lipicard Technologies:
Lipicard Technologies Limited develops innovative and novel High Therapeutic Index Drugs for Lipid management and cardio protection in collaboration with Life Enhancing Technologies LLC. USA. Platrol® is the first safe antiplatelet drug being developed for cardio-protection. Next in line are the integrated Lipid management drug for increasing HDL and lowering LDL, and safe NSAIDs.
Platrol® is registered trademarks of Life Enhancing Technologies.
Source: Lipicard Technologies
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
